Literature DB >> 27791236

The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer.

Nobuhiro Asai1, Eisuke Katsuda2, Rie Hamanaka1, Kenshi Kosaka1, Ayako Matsubara1, Masaki Nishimura1, Hiroyuki Tanaka1, Norihito Yokoe1, Ayumu Takahashi1, Etsuro Yamaguchi1, Akihito Kubo1.   

Abstract

INTRODUCTION: Patients with non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD) are at high risk of acute exacerbation of ILD (AE-ILD) when treated with systemic chemotherapy. Standard treatment for NSCLC complicated by ILD has not been established. PURPOSE AND METHODS: To examine whether the type of ILD categorized by the official ATS/ERS/JRS/ALAT statement as "idiopathic pulmonary fibrosis (IPF) by high-resolution computed tomography (HRCT)" could predict chemotherapy-induced AE-ILD in NSCLC patients with ILD, we retrospectively reviewed all patients with NSCLC complicated by ILD who had received chemotherapy at our institute from January 2007 until December 2013. Patients' characteristics, pathology and clinical staging of lung cancer, chemotherapy, type of ILD and AE-ILD during chemotherapy were evaluated. ILD was classified according to the statement as follows: usual interstitial pneumonia (UIP), possible UIP, and inconsistent with a UIP pattern.
RESULTS: A total of 46 patients had pre-existing ILD and received chemotherapy. The mean age was 73 years (range 46-83 years). Fifteen (32.6%) of 46 patients with ILD developed chemotherapy-induced AE-ILD, which was seen more frequently in patients with ILD with a UIP pattern or possible UIP pattern than in patients with a pattern inconsistent with UIP (80% versus 9.7%, p<0.001). Multivariate analyses including age, sex, performance status and radiographic patterns of ILD showed that the presence of a UIP or possible UIP pattern was an independent risk factor for chemotherapy-induced AE-ILD.
CONCLUSIONS: ILD with a UIP pattern or possible UIP pattern by the classification could be a risk factor for AE-ILD in NSCLC patients with ILD.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27791236     DOI: 10.5301/tj.5000574

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  5 in total

1.  Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease.

Authors:  Yuto Yasuda; Takashi Nomizo; Hiroaki Ozasa; Tomoko Funazo; Takahiro Tsuji; Hironori Yoshida; Yuichi Sakamori; Hiroki Nagai; Tomohiro Handa; Takeshi Kubo; Young Hak Kim
Journal:  Mol Clin Oncol       Date:  2017-08-11

2.  A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities.

Authors:  Jarushka Naidoo; Karthik Suresh
Journal:  Oncologist       Date:  2020-09-14

3.  Combination of Sequential Organ Failure Assessment (SOFA) score and Charlson Comorbidity Index (CCI) could predict the severity and prognosis of candidemia more accurately than the Acute Physiology, Age, Chronic Health Evaluation II (APACHE II) score.

Authors:  Nobuhiro Asai; Wataru Ohashi; Daisuke Sakanashi; Hiroyuki Suematsu; Hideo Kato; Mao Hagihara; Hiroki Watanabe; Arufumi Shiota; Yusuke Koizumi; Yuka Yamagishi; Hiroshige Mikamo
Journal:  BMC Infect Dis       Date:  2021-01-15       Impact factor: 3.090

4.  Risk factors for acute exacerbation in lung cancer complicated by interstitial lung disease with slight reticular shadows.

Authors:  Yutaka Takahara; Takuya Tanaka; Yoko Ishige; Ikuyo Shionoya; Kouichi Yamamura; Takashi Sakuma; Kazuaki Nishiki; Keisuke Nakase; Masafumi Nojiri; Ryo Kato; Shohei Shinomiya; Yuki Fujimoto; Taku Oikawa; Shiro Mizuno
Journal:  Thorac Cancer       Date:  2021-08-18       Impact factor: 3.500

5.  Risk Factors of Mortality From Pneumocystis Pneumonia in Non-HIV Patients: A Meta-Analysis.

Authors:  Yuqiong Wang; Xiaoyi Zhou; Maidinuer Saimi; Xu Huang; Ting Sun; Guohui Fan; Qingyuan Zhan
Journal:  Front Public Health       Date:  2021-06-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.